PROLONG
AMAG Pharmaceuticals’ shares fall 21% after failed Makena trial
March 11, 2019Sales and Marketing AMAG Pharmaceuticals, Makena, PROLONG, birth, trials
AMAG Pharmaceuticals’ Makena (hydroxyprogesterone caproate) has failed to meet its co-primary endpoints in a trial of patients with a history …
Latest content
EnteroBiotix appoints former GSK Chief Medical Officer to board
November 3, 2026
AI: an early warning system for patient safety
November 3, 2026
Highlighting the value of lab research for healthcare innovation
November 2, 2026
